Executive record
Alpha ID: alpha:person:nicole-murphyVersion: public-0As of: 2026-10-03
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Ms. Murphy has served as Executive Vice President, Pharmaceutical Operations and Technology since February 2022. She has held senior executive positions at Biogen since 2015 and previously served as Executive Director, Head of Supply Chain at Amgen, with a background in process development and engineering.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Board service coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageExecutive career
- 2026 to end not publishedExecutive title: Executive Vice President, Pharmaceutical Operations and Technology · Organization not publishedBIIB 10-K executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
BIIB 10-K executive officers
sec filing · Source published: Feb 6, 2026 · Retrieved: May 13, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 13, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 13, 2026
- Executive company: Executive at Biogen Inc. · Claim reviewed: May 13, 2026
- Executive title: Executive title: Executive Vice President, Pharmaceutical Operations and Technology · Claim reviewed: May 13, 2026
- Technology background: Technology background reported in filings · Claim reviewed: May 13, 2026
BIIB executive roster source
sec filing · Source published: Date unavailable · Retrieved: May 3, 2026
Supports 5 claims
- AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
- AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
- Executive company: Executive at Biogen Inc. · Claim reviewed: May 13, 2026
- Executive function: Technology Data Product (EVP) · Claim reviewed: May 3, 2026
- Executive title: Executive title: Executive Vice President, Pharmaceutical Operations and Technology · Claim reviewed: May 13, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-03
- Biography
- published
- Board service
- not observed
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope